Physician profile
Jessica E Weinstein
NPI 1609212448
$9,109.55
in general payments reported to CMS, 2019-2025
23 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $120 · 2021: $611 · 2022: $656 · 2023: $1,125 · 2024: $4,556 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164 · Honoraria: $3,091 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.62 |
| Honoraria | $3,091.00 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $2,698.08 | 2022-2024 | Syfovre |
| Alimera Sciences, INC. | $1,804.95 | 2019-2024 | Yutiq, Iluvien |
| Regeneron Pharmaceuticals, INC. | $660.99 | 2019-2024 | Eylea Hd |
| Astellas Pharma US INC | $536.17 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $511.87 | 2021-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $509.42 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $360.28 | 2020-2022 | |
| Genentech USA, INC. | $317.82 | 2019-2025 | Vabysmo, Susvimo |
| Dutch Ophthalmic, USA | $287.90 | 2021-2023 | Eva, Combined Machine, Tissueblue |
| Bausch & Lomb Americas INC. | $239.16 | 2024-2025 | |
| Eyepoint US, INC. | $187.71 | 2021-2024 | |
| Abbvie INC. | $150.02 | 2025 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Mallinckrodt Enterprises LLC | $128.50 | 2019 | |
| Rxsight INC | $109.88 | 2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.87 | 2019 | |
| Biogen, INC. | $104.58 | 2023 | |
| Novartis Pharmaceuticals Corporation | $78.51 | 2019 | |
| Alcon Vision LLC | $78.40 | 2023 | Constellation |
| Genentech, INC. | $64.80 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.64 | 2025 | Iluvien |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.